NCT03988608View on ClinicalTrials.gov

Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 9, 2019

Primary Completion Date

July 16, 2021

Study Completion Date

May 17, 2023

Conditions
Aplastic Anemia
Interventions
DRUG

Eltrombopag

Eltrombopag are film-coated tablets containing 25 mg of eltrombopag free acid in each tablet.

Trial Locations (5)

210000

Novartis Investigative Site, Nanjing

300020

Novartis Investigative Site, Tianjin

300052

Novartis Investigative Site, Tianjin

330006

Novartis Investigative Site, Nanchang

610041

Novartis Investigative Site, Chengdu

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY